Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia

Schizophrenia Research

Volumn 95, Issue 1-3, 2007, Pages 19-29

  Gaebel, Wolfgang ^a   Riesbeck, Mathias ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Early warning signs; Relapse prediction; Relapse prodromal symptoms; Schizophrenia

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEALTH PROGRAM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA;

ADULT; AFFECTIVE SYMPTOMS; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LOGISTIC MODELS; LONG-TERM CARE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RECURRENCE; ROC CURVE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY;

EID: 34548172141     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.06.016     Document Type: Article

References (42)

1. American-Psychiatric-Association (APA). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161 (2004) 1-56 (suppl.)
2. Birchwood M., Smith J., MacMillan F., Hogg B., Prasad R., Harvey C., and Bering S. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychological Medicine 19 (1989) 649-656
3. Bustillo J., Buchanan R.W., and Carpenter W.T. Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Schizophrenia Bulletin 21 (1995) 553-559
4. Davis J.M., Kane J.M., Marder S.R., Brauzer B., Gierl B., Schooler N., Casey D.E., and Hassan M. Dose response of prophylactic antipsychotics. Journal of Clinical Psychiatry 54 (1993) 24-30 (suppl)
5. Efron B., and Tibshirani R.J. An Introduction to the Bootstrap (1993), Chapman & Hall, New York
6. Gaebel W., Frick U., Köpcke W., Linden M., Müller P., Müller-Spahn F., Pietzker A., and Tegeler J. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse. British Journal of Psychiatry 163 suppl. 21 (1993) 8-12
7. Gaebel W., Jänner M., Frommann N., Pietzcker A., Köpcke W., Linden M., Müller-Spahn F., and Tegeler J. Prodromal states in schizophrenia. Comprehensive Psychiatry 41 suppl. 1 (2000) 76-85
8. Gaebel W., Jänner M., Frommann N., Pietzcker A., Köpcke W., Linden M., Müller P., Müller-Spahn F., and Tegeler J. First vs. multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research 53 (2002) 145-159
9. Gaebel W., Möller H.J., Buchkremer G., Ohmann C., Riesbeck M., Wölwer W., von Wilmsdorff M., Bottlender R., and Klingberg S. Pharmacological long-term treatment strategies in first episode schizophrenia. Study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 254 (2004) 129-140
10. Gaebel W., Falkai P., Weinmann S., and Wobrock T. Behandlungsleitlinie Schizophrenie. S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Edited by Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (2005), Steinkopf Verlag, Darmstadt
11. Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., Jockers-Scherübl, M.C., Kühn, K., Lemke, M., Bechdolf, A., Bender, S., Degner, D., Schlösser, R., Schmidt, L.G., Schmitt, A., Jäger, M., Buchkremer, G., Falkai, P., Klingberg, S., Köpcke, W., Maier, W., Häfner, H., Ohmann, C., Salize, H.J., Schneider, F., Möller, H.J., in press. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry.
12. Gleeson J.F., Rawlings D., Jackson H.J., and McGorry P.D. Early warning signs of relapse following a first episode of psychosis. Schizophrenia Research 80 (2005) 107-111
13. Herz M., and Melville C. Relapse in schizophrenia. American Journal of Psychiatry 137 (1980) 801-812
14. Herz M.I., and Lamberti S.J. Prodromal symptoms and relapse prevention in schizophrenia. Schizophrenia Bulletin 21 (1995) 541-551
15. Herz M.I., Lamberti J.S., Mintz J., Scott R., O'Dell S.P., McCartan L., and Nix G. A program for relapse prevention in schizophrenia. Archives of General Psychiatry 57 (2000) 277-283
16. Hirsch S.R., and Jolley A.G. The dysphoric syndrome in schizophrenia and its implications for relapse. British Journal of Psychiatry 155 suppl. 5 (1989) 46-50
17. Hsiao J.K., Bartko J.J., and Potter W.Z. Diagnosing diagnosis. Archives of General Psychiatry 46 (1989) 664-667
18. Jorgensen P. Early signs of psychotic relapse in schizophrenia. British Journal of Psychiatry 172 (1998) 327-330
19. Kane J.M. Management strategies for the treatment of schizophrenia. Journal of Clinical Psychiatry 60 Suppl 12 (1999) 13-17
20. Kraepelin E. Über paranoide Erkrankungen. Zeitschrift der Gesellschaft Neurologia ut Psychiatria 11 (1912) 617
21. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 160 (2003) 1209-1222
22. Liang K.Y., and Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
23. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., and Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry 50 (2001) 884-897
24. Malla A.K., and Norman R.M.G. Prodromal symptoms in schizophrenia: a prospective investigation. British Journal of Psychiatry 164 (1994) 487-493
25. Marder S.R., Wirshing W.C., Van Putten T., Mintz J., McKenzie J., Johnston-Cronk K., Lebell M., and Liberman R.P. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Archives of General Psychiatry 51 (1994) 280-287
26. National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance vol. 43 (2002). http://www.nice.org.uk www.nice.org.uk
27. Norman R.M.G., and Malla A.K. Prodromal symptoms of relapse in schizophrenia: a review. Schizophrenia Bulletin 21 (1995) 527-539
28. Nuechterlein K.H., and Dawson M.E. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophrenia Bulletin 10 (1984) 300-312
29. Pietzcker A., Gaebel W., Köpcke W., Linden M., Müller P., Müller-Spahn F., and Tegeler J. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study. Journal of Psychiatric Research 27 (1993) 321-339
30. Royal Australian and New Zealand College of Psychiatrists (RANZCP). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 39 (2005) 1-30
31. Seuchter S.A., Eisenacher M., Riesbeck M., Gaebel W., and Köpcke W. Methods for predictor analysis of repeated measurements: application to psychiatric data. Methods of Information in Medicine 43 (2004) 184-191
32. Shepherd M., Watt D., Falloon I., and Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine 19 Suppl 15 (1989) 1-46
33. Spitzer R.L., Endicott J., and Robins E. Research Diagnostic Criteria (RDC) (1978), Biometrics Research, New York State Psychiatric Institute, New York
34. Subotnik K.L., and Nuechterlein K.H. Prodromal signs and symptoms of schizophrenic relapse. Journal of Abnormal Psychology 97 (1988) 405-412
35. Tarrier N., Barrowclough C., and Bamrah J.S. Prodromal signs of relapse in schizophrenia. Social Psychology and Psychiatric Epidemiology 26 (1991) 157-161
36. Watt D.C., Katz K., and Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of standardized clinical and social assessment. Psychological Medicine 13 (1983) 663-670
37. van Meijel B., van der Gaag M., Kahn R.S., and Grypdonck M.H. Recognition of early warning signs in patients with schizophrenia: a review of the literature. International Journal of Mental Health Nursing 13 (2004) 107-116
38. Weiden P.J., and Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bulletin 21 (1995) 419-429
39. Wiersma D., Nienhuis F.J., Sloof C., and Giel R. Natural course of schizophrenic disorders: a 15 year follow-up of a Dutch incidence cohort. Schizophrenia Bulletin 24 (1998) 78-85
40. Wölwer W., Buchkremer G., Häfner H., Klosterkötter J., Maier W., Möller H.J., and Gaebel W. German research network on schizophrenia - bridging the gap between research and care. European Archives of Psychiatry and Clinical Neuroscience 253 (2003) 321-329
41. Wunderink L., Nienhuis F.J., Sytema S., Slooff C.J., Knegtering R., and Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. Journal of Clinical Psychiatry 68 (2007) 654-661
42. Yung A.R., and McGorry P.D. The prodromal-phase of first-episode psychosis: past and current conceptualizations. Schizophrenia Bulletin 22 (1996) 353-370